Ligand Pharmaceuticals LGND Phase 3 clinical trial — Gross contract asset
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetGross.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset?
- Ligand Pharmaceuticals (LGND) reported phase 3 clinical trial — gross contract asset of $10M in Q1 2026.
- How has Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset changed year-over-year?
- Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset decreased by 0.0% year-over-year, from $10M to $10M.
- What is the long-term trend for Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's phase 3 clinical trial — gross contract asset has grown at a 0.0% compound annual growth rate (CAGR), from $40M to $40M.
- What does phase 3 clinical trial — gross contract asset mean?
- This metric represents the total gross value of contract assets recognized for drug programs currently undergoing Phase 3 clinical trials. It reflects the cumulative revenue recognized for milestone achievements or licensing obligations that have been earned but not yet billed or collected under existing partnership agreements. This asset serves as a key indicator of the company's progress in advancing partnered pipeline assets toward commercialization and potential royalty generation.